Russia Medical Device Safety Monitoring under Order No. 540n

1. Key takeaways

The safety monitoring procedure for medical devices approved by Order No. 540n of the Ministry of Health of the Russian Federation, dated 26 May 2026, replaces Order No. 980n (dated 15 September 2020) with effect from 1 September 2026, and remains in force until 1 September 2032. The scope boundary is written directly into the title of the document: it applies to all medical devices except those registered under international treaties and under acts that form the law of the Eurasian Economic Union. Devices registered at the Union level therefore continue to be governed by EEC Decision No. 174, which means that many portfolios will run two parallel safety-monitoring regimes side by side, depending on how each registration certificate was obtained.

Three practical conclusions follow immediately. First, the transition date of 1 September 2026 leaves no grace period for organisations that are still operating under the old rules, so internal procedures must be updated before that date. Second, the new procedure deliberately lowers the threshold for what counts as reportable information, by unifying previously separate concepts into a single entry point. Third, the obligations are not limited to manufacturers: every organisation that participates in the circulation of medical devices is drawn into the monitoring chain, which makes coordination with authorised representatives, importers and user organisations an explicit part of the compliance workload.

2. Legal basis

The table below summarises the instruments that define the Russian safety monitoring regime, together with the specific provisions cited in this guide. The old procedure of Order No. 980n applies only until 31 August 2026, so the date of entry into force of Order No. 540n is also the date on which the previous framework formally expires.

3. Expert insights

Insight 1: the conceptual system has been rebuilt. The former procedure distinguished between separate concepts such as side effects, adverse reactions, device interactions and situations threatening life and health. Order No. 540n consolidates all of these into a single entry concept of the adverse event (нежелательное событие). The practical effect is a lower identification threshold and broader coverage: staff on the ground no longer need to classify an observation into a legal category before it enters the reporting pipeline. For quality teams, this means that triage criteria in internal SOPs must be rewritten, because criteria calibrated against the old vocabulary will systematically under-report under the new one.

Insight 2: the data sources are explicitly listed for the first time, in four categories. They are: (1) adverse event reports; (2) data sent automatically to the RZN information system by AI medical device software equipped with automatic upload functionality; (3) post-market clinical monitoring (ПКМ) reports submitted by manufacturers of class 3 devices and class 2b implantable devices; and (4) information provided by manufacturers, authorised representatives or importers. Listing the sources in the order itself is significant: it signals that the regulator expects the data stream to be continuous and multi-channel rather than dependent on sporadic human reporting, and it gives manufacturers a checklist of the flows they must be able to demonstrate.

Insight 3: the obligations fall on every participant in circulation. Apart from natural persons, every organisation participating in the circulation of medical devices must define its information collection methods in internal documents and designate a responsible person (p. 5). The duties of that person are set out in p. 6: preparing and submitting reports, periodically reviewing safety letters issued by RZN, taking measures to prevent harm, and recording events and informing the relevant parties without delay. In addition, organisations that use devices must provide access to the device for investigation purposes (p. 4). Distributors and healthcare facilities therefore cannot treat vigilance as the manufacturer’s problem alone; their own internal documentation is now a regulatory requirement in its own right.

4. Practical recommendations

The following actions will position a portfolio correctly before the new procedure takes effect, and are ordered by the sequence in which most organisations will need to complete them.

1. Complete the appointment of the responsible person, and establish internal procedures and event logs, before 1 September 2026 — do not wait until the rules are already in force to begin rewriting them.
2. For drug-device combination products, confirm rule by rule, certificate by certificate, which regime applies (Order No. 540n or EEC Decision No. 174), and record the conclusion in the product file.
3. For AI software products, build a closed loop for automatically uploaded data covering reception, assessment and onward submission, so that machine-generated data reaches the RZN information system without manual gaps.
4. Train channel staff — distributors, service organisations and clinical users — on the lowered identification threshold, since the single adverse event concept means observations that were previously ignored are now reportable.
5. File the safety letters received from RZN and document the periodic review of them, because p. 6 makes that review a duty of the named responsible person rather than a courtesy.

5. Verification checklist

Use the checklist below as a gate before 1 September 2026, and re-run it whenever the responsible person changes or the internal procedure is revised.

• □ Appointment of the responsible person is complete and documented in writing
• □ Information collection methods, report formats and submission routes are written into internal procedures
• □ The applicable rules for each device (Order No. 540n / EEC Decision No. 174) are marked in the product file
• □ A processing workflow for automatically uploaded AI software data has been established
• □ Clauses on assistance with device access for investigations are written into service agreements with user organisations
• □ The review of RZN safety letters is scheduled and assigned to a named owner

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers, authorised representatives and importers across the full Russian post-market compliance cycle, including vigilance reporting, recalls and corrective actions, and preparation for federal state supervision. If you need help aligning your safety monitoring procedures with Order No. 540n before 1 September 2026, contact us at info@grzanglobal.com.